Abstract
The inhibitory effects of madroxiprogesterona acetate on clinical features of precocious puberty is well known, but the effects on growth are still controversial. To determine the final heights of patients treated with MPA (150 mg every week) for a period longer than one year (X+SD 3.24+1.85 years) data from a group of 26 girls were analyzed. Chronological age at the onset of treatment was 5.84+2.05 years, bone age was 8.24+2.87 years and the haight standard deviation score was 1.56+1.15. Chronological age at withdrawal of treatment was 9.45+0.79 years and bone age 12.95+1.14 years. Attained final height was 155.6+8.06 on (-1.1 SD of the normal population). In a group of 8 untreated girls with precocious puberty the adult height was 149.2+5.07 cm (−2.16 SD, p 0.02).
In 9 patients in whom treatment was stopped at a bone age equal or below 12 years final height was 159.2+10.05 on while in 16 girls who had a bone age over 12 years at the moment of the withdrawal final height was 153.3+6.28 on (p 0.05).
Our data demonstrated the effectiveness of MPA treatment on ultimate height in precocious puberty. The best height observed in those patients who stopped treatment at a bone aga lower than 12 years suggests that discontinue therapy before reaching that degree of skeletal maturation may be advantageous.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boulgourdjian, E., Martínez, A., Escobar, M. et al. 35 FINAL HEIGHT IN GIRLS PRECOCIOUS PUBERTY TRAFATED WITH MEDROXI-PROGESTERONE ACETATE (moa). Pediatr Res 32, 255 (1992). https://doi.org/10.1203/00006450-199208000-00058
Issue Date:
DOI: https://doi.org/10.1203/00006450-199208000-00058